BioSpace News Archive

Foundation Grant Builds on Earlier Donation from Air Products China to Support Local Relief Efforts

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, announces the recent publication of a peer-reviewed manuscript: the first comprehensive review of somatic mosaicism in Fanconi Anemia (FA) in the journal Annals of Hematology.

BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced it has appointed Ronald J. Daniels, president of Johns Hopkins University, to its board of directors, effective immediately.

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with high unmet medical need, today reported its fourth-quarter and full-year 2019 financial results, and provided recent corporate and program highlights.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will participate in four upcoming investor conferences.

MyoKardia, Inc. (Nasdaq: MYOK), today announced that Taylor Harris, Chief Financial Officer, will present at the 40th Annual Cowen Health Care Conference on Monday, March 2nd 2020 at 1:30 p.m. EST in Boston.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced that its partner, Bristol-Myers Squibb, has initiated a randomized Phase 2 cohort expansion in its ongoing first-in-human Phase 1/2a trial of the anti-CTLA-4 Probody BMS-986249 alone and in combination with Opdivo® (nivolumab).

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), today announced that Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will present a corporate overview at the 40th Annual Cowen & Co. Health Care Conference

COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it has entered into a license agreement with Kansas State University Research Foundation (“KSURF”) to further develop certain proprietary broad-spectrum antiviral compounds for the treatment of Norovirus and Coronavirus infections.

Including Statistically Significant Achievement of Composite Endpoint of Both Fibrosis Improvement and Resolution of NASH versus Placebo